Diagnostic and Prognostic Roles of Universal Estrogen Receptor Testing in Endometrial Carcinoma.

Authors

Jutta Huvila

Published in

Surgical pathology clinics. Volume 19. Issue 4. Pages 541-552. Epub Aug 11, 2026.

Abstract

Estrogen receptor (ER) immunohistochemical evaluation has emerged as a key variable in the risk assessment of endometrial carcinoma. In the most common molecular subtype of endometrial carcinomas, the no specific molecular profile, ER is used in conjunction with stage, grade, and lymphovascular space invasion (LVSI) for risk assessment and guiding adjuvant treatments. Additionally, ER is a useful tool for aiding primary site and histotype assessment and has a role in predicting response to hormonal therapies for endometrial carcinoma. These applications of ER immunostaining will be reviewed.

PMID:
42951384
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.